FDA eases outsourcing facility ibuprofen compounding for hospitals
![stock-doctor-prescription-bottles_900x400](/sites/default/files/styles/900x400/public/2018-04/stock-doctor-prescription-bottles_900x400.jpg?itok=P-l0VV5j)
To help hospitals and health systems meet demand during the current surge in respiratory illnesses for fever-reducing products to treat pediatric patients and adults unable to swallow solid oral dosage forms, the Food and Drug Administration Friday released guidance for outsourcing facilities compounding certain ibuprofen oral suspension products.
“Although FDA is monitoring the global pharmaceutical supply chain and working, within its authorities, with manufacturers of approved ibuprofen oral suspension products, to bolster supply, temporary flexibility is needed to help ensure that treatment options are available to hospitals and health systems during this period of increased demand,” the guidance states.
Related News Articles
Headline
The Centers for Disease Control and Prevention has issued an advisory alerting health care providers, laboratory professionals and others in health care…
Headline
The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active…
Headline
The AHA sent a letter June 28 to the U.S. Trade Representative responding to a proposed increase in Section 301 tariffs for goods produced in China, which…
Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of…